Study warns of hidden dangers in blood disorder treatment
NCT ID NCT05876221
Summary
This study looked back at 223 adults with a rare, serious blood clotting disorder (aTTP) who were treated with the drug caplacizumab. Researchers analyzed how patients' platelet counts changed after starting the drug to identify common patterns and potential pitfalls. The goal is to help doctors better predict these responses and avoid over- or under-treating patients based on misleading platelet count changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Cologne
Cologne, Germany
Conditions
Explore the condition pages connected to this study.